Document is current

Article History

Received: 4 March 2026

Accepted: 12 May 2026

First Online: 24 June 2026

Declarations

Competing interests: The authors declare no competing interests.

Ethics approval and consent to participate: The study involving human blood samples was conducted in accordance with the Declaration of Helsinki. Ethical approvals were obtained from the University of the Punjab Ethical Committee (IBB/25/101-C), and Artois University (102C25/38). Informed consent was obtained from all volunteers.

Ethical standards: We undersigned the article titled “Exploring the Therapeutic Potential of Tamoxifen Conjugated ZnO Nanoparticles for Cancer Treatment.” We approve the proof for publication in an upcoming issue. We declare that our work is original and is not being considered for potential publication elsewhere. All the authors agree with the content of the manuscript. We hereby acknowledge the submission to the journal.

Cell lines: The human breast cancer cell line MCF-7 was obtained from ATCC. STR profiling and routine testing for mycoplasma contamination authenticated the cell line. The cells were cultured in high-glucose DMEM supplemented with 10% FBS and 1% penicillin‒streptomycin at 37 °C in a humidified atmosphere containing 5% CO 2 .